Neuronetics and BrainsWay announced a cross-licensing agreement this week, ending litigation that had been pending since 2022 over coil design patents. Under the agreement, both companies receive perpetual access to a defined set of each other's patents in exchange for royalty arrangements that were not publicly disclosed.
The two companies represent the dominant share of the U.S. TMS device market. Neuronetics' NeuroStar is the most widely deployed system in private practice, while BrainsWay's H-coil deep TMS is the only FDA-cleared device for OCD and smoking cessation.
Industry analysts expect the resolution to reduce per-session device costs at clinics by 10-15% over the next 18 months as licensing certainty enables more aggressive distribution and pricing. Both companies signaled that R&D investment will refocus on next-generation targeting and personalization rather than on incremental coil engineering.
The settlement does not affect ongoing disputes between either company and several smaller TMS device makers, including international entrants seeking U.S. market clearance.
Source
Reporting based on coverage from MedTech Dive. This article is editorial summary intended for general information; it is not medical advice.